Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 253 results found. Search for [ Pfizer COVID-19 vaccine trials india ]

Results 100 to 120 of 253
Reuters
December 2, 2020
The move to grant emergency authorisation to the Pfizer/BioNTech vaccine has been seen by many as a political coup for UK Prime Minister Boris Johnson, who has led his country out of the EU


BusinessToday.In
December 2, 2020
The stock has risen 3.32% in the last 2 days of consecutive gain. Market capitalisation of the firm stood at Rs 23,994 crore today


PTI
December 2, 2020
After playing a critical role in transporting essentials and medical supplies during the lockdown, SpiceXpress, has come forth to take up the responsibility of seamlessly transporting the vaccine through a specialised service called Spice Pharma Pro


Manoj Sharma
December 2, 2020
Pfizer and BioNTech vaccine: The UK has already ordered 40 million doses of the Pfizer vaccine to vaccinate its 20 million population, of which around 10 million doses will be available soon


BusinessToday.In
December 1, 2020
Balram Bhargava, Director General of Indian Council of Medical Research (ICMR), said that the primary objective of vaccination is to break the COVID-19 transmission chain


BusinessToday.In
November 30, 2020
There are only five companies that have given preliminary data about how effective their vaccines could be to fight against coronavirus. These five companies include Pfizer-BioTech, Moderna Inc, Oxford University-AstraZeneca Plc, and Gamaleya Institute


PB Jayakumar
November 28, 2020
Serum Institute will have a capacity to make over 2.5 billion doses of vaccines a year as it is currently upscaling the capacity from over 1.6 billion doses  


Reuters
November 28, 2020
Vaccines by Pfizer and BioNtech, as well as Moderna and AstraZeneca have shown promising results in large clinical trials, but there is no question of \"cutting corners\", said Thomas Cueni, director-general of the IFPMA


BusinessToday.In
November 27, 2020
After the publication of early data from phase-3 clinical trials, drugmakers Pfizer and BioNTech have sought regulatory approval to deploy their inoculation under emergency-use rules. American biotech company Moderna is also likely to do the same soon


Manoj Sharma
November 27, 2020
New vaccines are rarely certified for efficacy above 90 per cent. Their efficacy improves as millions are vaccinated over decades. In fact, most vaccines get certified in the 40-60 per cent efficacy band


BusinessToday.In
November 27, 2020
The company could be looking at manufacturing 100 million doses to begin with, as per Chairman Pankaj Patel.


Rajeev Dubey
New Delhi, November 25, 2020
In stark contrast to the mayhem around the world, India's top three candidates - Serum-Oxford, Bharat Biotech and Zydus Cadila continued their scientific pursuits unobtrusively (the fourth, DRL-Gamaleya, just started India trials). At least 16 more vaccines are under development at home


PB Jayakumar & Joe C Mathew
New Delhi, November 25, 2020
The world of vaccine and drug development is being reset. Here's how Indian pharma must reinvent to lead the new era of drug discovery and research


PB Jayakumar & Joe C Mathew
New Delhi, November 25, 2020
A blow-by-blow account of how Indian vaccines are being readied


Aseem Thapliyal
November 25, 2020
Sensex climbed 302 points to 44,825 and Nifty gained 90 points to 13,145


Reuters
November 24, 2020
Brent crude rose 51 cents, or 1.1%, to $46.57 a barrel by 1322 GMT and hit a session high of $46.72, its highest since March 6. U.S. West Texas Intermediate crude gained 63 cents, or 1.5%, to $43.69


Joe C Mathew
November 24, 2020
The announcement that comes a day after Oxford-Astrazeneca announced a similar level of efficacy for its COVID-19 vaccine allows India to hope for two vaccines to fight the COVID-19 pandemic in the country


BusinessToday.In
November 24, 2020
Vardhan says it makes no sense to consider Pfizer as pharma major is yet to get approval in the US. After requisite approvals, US pharma major will have to cater to needs of its own country's population first


BusinessToday.In
November 23, 2020
Centre is worried about the caseload surge in urban centres, which has resulted in the enforcement of measures such as curfews by state governments.


BusinessToday.In
November 23, 2020
The panel-led by Dravida Munnetra Kazhagam (DMK) lawmaker Kanimozhi Karunanidhi will hear officials of pharmaceutical departments on the status of the COVID-19 vaccine


PAGES 6 OF 13  678910